InsiderTrades.com logo
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

ATH Insider Trading

Insider Ownership Percentage: 15.00%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Alterity Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Alterity Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alterity Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 12/16/2022 11:07 AM ET

This chart shows the closing price history over time for ATH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
It’s finally here…
From ProTrading Research   |   Ad
Our analysts have finally finished the report we’ve all been waiting for.

The Top Five Ai Stocks that are part of the new AI Gold Rush happening in the world right now.

5 years from now, you just might wish you’d gotten in early on these stocks.
Click here to get the names of all 5 companies

Alterity Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2022Brian MeltzerInsiderExpiry1,250,000A$0.01A$12,500.00
See Full Table
It’s finally here…
From ProTrading Research   |   Ad
Our analysts have finally finished the report we’ve all been waiting for.

The Top Five Ai Stocks that are part of the new AI Gold Rush happening in the world right now.

5 years from now, you just might wish you’d gotten in early on these stocks.
Click here to get the names of all 5 companies

SEC Filings (Institutional Ownership Changes) for Alterity Therapeutics (ASX:ATH)

0.33% of Alterity Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Read More on Alterity Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Who are the company insiders with the largest holdings of Alterity Therapeutics?

Alterity Therapeutics' top insider investors include:
  1. Brian Meltzer (Insider)
Learn More about top insider investors at Alterity Therapeutics.
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!